Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise for slowing kidney disease in Non-Diabetic patients

NCT ID NCT06835322

Disease control Sponsor: Alexandria University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether finerenone, a drug that blocks a hormone involved in kidney damage, can reduce protein in urine and slow kidney function decline. One hundred adults with non-diabetic glomerulonephritis took either finerenone or a placebo for 9 months, on top of their usual treatments. The goal is to see if finerenone can help protect the kidneys from further damage.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Finerenone (a drug that blocks a hormone to protect the kidneys)
What this could lead to
If it works, finerenone could become an add-on treatment to slow kidney damage and delay dialysis or transplant in people with non-diabetic glomerulonephritis.
What could go wrong
This is a small, phase 2 trial with only 100 participants, so results may not apply to everyone. Finerenone can raise potassium levels, which is a known risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

100 people

The number who actually took part.

Started

Apr 2025

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. GN patients on maximum tolerated doses of an ACEi or ARBs together with their immunosuppression protocol (if needed) for at least 4 weeks. 2. urinary protein excretion \>500 mg/g. 3. Adult patients with age above 18 years. 4. eGFR ≥ 25 mL/ min/1.73 m2. 5. baseline serum potassium level \<5 mEq/L. Exclusion Criteria: 1. Patients with diabetes mellitus (type 1 or 2). 2. Other non-glomerular kidney diseases. 3. Heart failure. 4. Breast feeding or pregnancy. 5. Patients who received medications to treat hyperkalemia 4 weeks before study. 6. Uncontrolled hypertension (BP \> 160/100).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glomerulonephritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glomerulonephritis proteinuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glomerulonephritis

Contacts and locations

Locations

  • Faculty of Medicine, Aexandria University

    Alexandria, 21526, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.